Chicago Islet Consortium ICR at UIC

UIC 的芝加哥小岛联盟 ICR

• 批准号: 7168151
• 负责人: Jose Oberholzer
• 金额: $ 106.08万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7168151
• 关键词: cell transplantation; clinical research; human; insulin; pancreas; pancreatic islets; transplantation; university

DESCRIPTION (provided by applicant): Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and fuel them. It is estimated that 20.8 Million Americans have diabetes; type I diabetes accounts for 5 to 10% of cases (approximately 1.56 Million type I diabetic patients). Keeping blood glucose levels under tight control represents the most effective way either to prevent the onset or to reduce the progression of the chronic complications of type I diabetes, such as blindness, kidney failure and cardiovascular diseases. Islet transplantation can achieve insulin independence, glucose control and freedom of hypoglycemic attacks in patients afflicted with Type I diabetes mellitus. However, the recovery of functional pancreatic islets from cadaveric donor pancreata is a complex procedure and needs to be optimized. Until an unlimited source of human pancreatic islet cell becomes available, the further development of endocrine replacement therapy for the treatment of diabetes will solely depend on the availability of high quality islet preparations, both for clinical application and laboratory-based research. Because of the complexity of the islet isolation procedure, it would be desirable to concentrate the know-how in a limited number of centers or consortiums to allow for optimal use of available resources. The aim of this application is to extend the existing human islet core facility at the University of Illinois and the Chicago Islet Consortium into a federally funded Islet Cell Resource Center to isolate, purify, characterize and distribute human pancreatic islet cells for both transplantation into diabetic patients and use in laboratory studies to a larger community. The ICR at UIC with its partners in the Chicago Islet Consortium will be responsible for the procurement of whole pancreata, isolation and quality control of islet cell preparations, and distribution of islets for approved research or clinical protocols. The ICR at UIC is conducting research and development to improve isolation techniques, cellular viability and function, and shipping procedures, and is investigating methods for improved assessment of islet mass, composition, quality and viability. In addition, and most importantly for the progress of the field, the ICR at UIC will continue to provide large numbers of high-quality islet preparations for transplantation in diabetic patients.

描述（由申请人提供）：I型糖尿病是由于人体未能产生胰岛素的激素而引起的，该激素“解锁”了人体细胞，从而使葡萄糖可以进入并加油。据估计，有2080万美国人患有糖尿病。 I型糖尿病占病例的5％至10％（约15.6万I型糖尿病患者）。保持血糖水平在严格的控制下是防止发作或减少I型糖尿病慢性并发症的最有效方法，例如失明，肾衰竭和心血管疾病。胰岛移植可以在患有I型糖尿病的患者中实现胰岛素独立性，葡萄糖控制和降血糖发作的自由度。但是，从尸体供体胰腺中恢复功能性胰岛是一个复杂的过程，需要优化。直到可用的人类胰岛细胞的无限来源可获得，用于治疗糖尿病的内分泌替代疗法的进一步发展将仅取决于用于临床应用和基于实验室的研究的高质量胰岛制剂的可用性。由于胰岛隔离程序的复杂性，希望将专有技术集中在有限数量的中心或财团中，以最佳地使用可用资源。该应用的目的是将伊利诺伊大学和芝加哥胰岛财团的现有人类胰岛核心设施扩展到一个由联邦资助的胰岛资源中心，以隔离，纯化，表征和分发人类胰岛细胞，以将两种移植到糖尿病患者中并将其用于更大的社区的实验室研究。 UIC的ICR及其在芝加哥胰岛财团的合作伙伴将负责整个胰腺的采购，胰岛细胞制备的隔离和质量控制，以及用于认可的研究或临床方案的胰岛分布。 UIC的ICR正在进行研发，以改善隔离技术，细胞活力和功能以及运输程序，并正在研究改善评估胰岛质量，组成，质量和生存能力的方法。此外，最重要的是，对于该领域的进步，UIC的ICR将继续为糖尿病患者的移植提供大量的高质量胰岛准备。